ProNAi Therapeutics is applying proprietary, nucleic acid-based DNA interference technology (DNAi®) to discover and develop novel therapeutic approaches for cancer. The company’s most advanced drug candidate, PNT2258, is expected to advance toward clinical trials in 2008 based on striking preclinical activity in hematological and solid tumor models.

The company was founded in 2004 by pharmaceutical researchers and scientists who have substantial experience in the area of nucleic acid research. The founders developed DNAi® and leveraged this to successfully design a new class of therapies.
In March 2008, ProNAi received approval to proceed into Phase 1 clinical testing from the FDA for its lead product candidate, PNT2258. ProNAi will continue to  research into potential cancer therapies .

To date, the company has successfully recruited a seasoned senior management team and a Board of Directors with a proven track record in discovery research, research operations, product development, and business development. ProNAi’s Scientific Advisory Board has significant experience in nucleic acid research, and clinical trial design and development.